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Objective: Metabolic abnormalities are common long-
term side effects of antiretroviral treatment. In this
study we investigated the prevalence of dyslipidemia and
metabolic abnormalities in 2 groups of HIV-infected patients
receiving highly active antiretroviral therapy (HAART) and
antiretroviral-naive patients.
Methods: 40 HIV infected patients treated by HAART as a
case group and 15 HIV naive, as a control group enrolled in
this study. The two groups were well balanced with respect
to age, sex, CD4 cell counts.
Results: Levels of total cholesterol, triglycerides, and
lactate were elevated in 24%, 37%, and 25% of patients,
respectively. The prevalence of elevated triglyceride and
cholesterol levels was signiﬁcantly higher among patients
receiving antiretroviral therapy than it was among those
who were not receiving treatment. Fasting hyperglycemia
was noted in 11% of patients overall, but this was not signif-
icantly associated with antiretroviral treatment group. Low
HDL levels were noted in 44.4% of patients overall, and this
ﬁnding did not vary by treatment group. We found signiﬁ-
cant difference regarding mean of total cholesterol and LDL
between treated group and controls (P < 0.05).No signiﬁcant
difference was observed in mean of HDL, Lactate and fasting
blood sugar levels between each treated group and controls.
Conclusion: We concluded that in HIV infected patients
with exposure to HAART, hyperlipidemia was a common
metabolic complication. The prevalence of metabolic abnor-
malities in Iranian HIV-infected patients was similar to those
reported for Western and Asian studies.
doi:10.1016/j.ijid.2008.05.496
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HIV Infection, HAART, and Gynecomastia. Epidemiologi-
cal, Clinical, and Pathogenetic Correlates
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Background: Gynecomastia (G) is an emerging untoward
event in patients treated with HAART.
Patients and Methods: Through a cross-sectional study
performed on around 1,000 HIV-infected patients (p) treated
with antiretrovirals at our reference centre in Bologna
(Italy),we identiﬁed all cases of G related to the admin-
istration of at least 12 consecutive months of HAART,to
assess possible correlations of G with a spectrum of clini-
cal,laboratory,and therapeutic variables (and including all
adverse effects of HAART itself). All p with true G (as distin-
guished from lipomastia by an ultrasonography assay) were
considered evaluable,while p with other predisposing con-
ditions (endocrine disease,alcohol abuse,liver cirrhosis,and
use of drug possibly predisposing to G), were carefully
excluded.
Results: Twenty-one out of 616 evaluable HIV-infected
male p (3.4% of our p population), developed a true G
when aged 12—58 years. Seven p out of 21 never received
protease inhibitor (PI)-containing therapies,while efavirenz-
based regimens apparently prompted G in seven p who were
na¨ıve for PI,and worsened this disturbance in three further p
who abandoned PI for efavirenz.Considering nucleoside ana-
logues (NA), two p developed G during treatment conducted
with dual isolated NA. Comparing the different administered
NA,stavudine seemed to be the most commonly used com-
pound, also taken for the longest time (p < .01).A complete
hormonal workup did not detect signiﬁcant abnormalities,
save in one p, who had slight serum FSH,LH,and testos-
teron abnormalities (with normal prolactin levels).When
considering the eventual correlation with the most common
HAART-induced disturbances,some forms of lipodystrophy
was concurrent in all the 21 p with G,while hypertriglyc-
eridemia,hypercholesterolemia,and hyperglycemia were
found in 15,9,and three p, respectively. During the subse-
quent 12—36-month follow-up, a spontaneous ameliorement
of G was never observed,notwithstanding eventual HAART
modiﬁcations.Due to local hypersthesia,tenderness,and dis-
comfort,two p resorted to surgery.
Conclusions: G is probably an underestimated problem
in the setting of HAART.The frequent association of G with
other HAART-related dysmetabolism suggests possible com-
mon pathogenetic causes.
doi:10.1016/j.ijid.2008.05.497
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Background: Higher incidences of symptomatic hyperlac-
tatemia (SHL) and lactic acidosis (LA) have been reported
